Evidence map›Paper›PMID 34918931›Full record

ArticleJournal of medicinal chemistry2022

Derivatives of (

Fabao Zhao, Unai Atxabal, Sofia Mariottini, Feng Yi, James S Lotti, Nirvan Rouzbeh, Na Liu, Lennart Bunch, Kasper B Hansen, Rasmus P Clausen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Design of (Journal of medicinal chemistry · 2025
    Article
  3. Article
  4. Discovery of GluN2A subtype-selectiveActa pharmaceutica Sinica. B · 2024
    Review
  5. Article
  6. Discovery of (Frontiers in chemistry · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Fabao ZhaoDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen DK-2200, Denmark.
Unai AtxabalDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen DK-2200, Denmark.
Sofia MariottiniDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen DK-2200, Denmark.
Feng YiCenter for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana 59812, United States.
James S LottiCenter for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana 59812, United States.
Nirvan RouzbehCenter for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana 59812, United States.
Na LiuDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen DK-2200, Denmark.
Lennart BunchDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen DK-2200, Denmark.ORCID 0000-0002-0180-4639
Kasper B HansenCenter for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana 59812, United States.ORCID 0000-0002-3303-4819
Rasmus P ClausenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen DK-2200, Denmark.ORCID 0000-0001-9466-9431
University of Copenhagen · DKUniversity of Montana · US

Funding

Surveillance genome sequencing to detect SARS-CoV-2 virus variants in MontanaP20GM103546 · NIGMS · UNIVERSITY OF MONTANA · PI BOWLER, BRUCE E · 2012 to 2021
$19.2M
Structural and functional investigation of negative allosteric NMDA receptor modulationR01NS097536 · NINDS · UNIVERSITY OF MONTANA · PI Kasper Boe Hansen · 2016 to 2026
$3.4M
Physiology and pharmacology of GluN3-containing NMDA receptorsR01NS116055 · NINDS · UNIVERSITY OF MONTANA · PI HANSEN, KASPER BOE · 2021 to 2025
$1.8M
NIGMS NIH HHS P20 GM103546NINDS NIH HHS R01 NS097536NINDS NIH HHS R01 NS116055
6 · The paper itself

Abstract

NMDA receptors mediate glutamatergic neurotransmission and are therapeutic targets due to their involvement in a variety of psychiatric and neurological disorders. Here, we describe the design and synthesis of a series of (

Indexed as

AnimalsCarrier ProteinsExcitatory Amino Acid AgonistsGlycineHumansMembrane ProteinsModels, MolecularNerve Tissue ProteinsReceptors, N-Methyl-D-AspartateStructure-Activity RelationshipXenopusXenopus laevisCarrier ProteinsExcitatory Amino Acid AgonistsGlycineGPRIN2 protein, humanMembrane ProteinsNerve Tissue ProteinsReceptors, N-Methyl-D-Aspartate

Identifiers

PMID34918931
PMCPMC9437973
OpenAlexW4200606041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.